GNTA

News

globenewswire.comGenenta signs Definitive Agreements with Sophia High Techglobenewswire.comApr 23

globenewswire.comGenenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programsglobenewswire.comMar 27

globenewswire.comGenenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldiniglobenewswire.comMar 24

Trade GNTA

About Genenta Science S.p.A.

Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.

CEO: Pierluigi Paracchi
IPO Date: Dec 15, 2021

Market Data

Open: $1.75
High: $1.88
Low: $1.68
Volume: 135K
Avg Volume: 1.4M
52W High: $10.00
52W Low: $0.55

Valuation

Market Cap: $32M
Enterprise Value: $30M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-6.9M
Revenue: $0
Net Income: $-6.3M
Cash: $5.5M
Debt: $7.6M

Events

EarningsSep 2

EPS est. -0.27607